UNIVERSITY OF LEEDS

This is a repository copy of Mechanism of regulation of pantothenate biosynthesis by the PanD-PanZ.AcCoA complex reveals an additional mode of action for the antimetabolite *N*-pentyl pantothenamide (N5-Pan).

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/120576/

Version: Supplemental Material

Article:

Arnott, ZLP, Nozaki, S, Monteiro, DCF et al. (4 more authors) (2017) Mechanism of regulation of pantothenate biosynthesis by the PanD-PanZ.AcCoA complex reveals an additional mode of action for the antimetabolite N-pentyl pantothenamide (N5-Pan). Biochemistry, 56 (37). pp. 4931-4939. ISSN 0006-2960

https://doi.org/10.1021/acs.biochem.7b00509

© 2017 American Chemical Society. This document is the Accepted Manuscript version of a Published Work that will appear in final form in Biochemistry, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see https://doi.org/10.1021/acs.biochem.7b00509. Uploaded in accordance with the publisher's self-archiving policy.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



Supplementary information for:

Mechanism of regulation of pantothenate biosynthesis by the PanD-PanZ.AcCoA complex reveals an additional mode of action for the antimetabolite N-pentyl pantothenamide (N5-Pan)

Zoe L. P. Arnott^{†1}, Shingo Nozaki^{‡1}, Diana C. F. Monteiro^{†§}, Holly E. Morgan[†], Arwen R. Pearson[§], Hironori Niki^{‡1} and Michael E. Webb^{†*}

†Astbury Centre for Structural Molecular Biology and School of Chemistry, University of Leeds, Leeds LS2 9JT, UK; ‡Microbial Genetics Laboratory, Genetics Strains Research Center, National Institute of Genetics, 1111 Yata, Mishima, Shizuoka 411-8540, Japan; §Hamburg Center for Ultrafast Imaging, Institute of Nanostructure and Solid State Physics, University of Hamburg, Luruper Chaussee 149, Hamburg 22761, Germany; ⊥Department of Genetics, Graduate University for Advanced Studies (Sokendai), 1111 Yata, Mishima, Shizuoka 411-8540, Japan

Contents

Figures S1-S7	S 3
Experimental methods	S 10
Analytical data for pentyl pantothenamide and ethyldethiacoenzyme A	S14

Figure S1 Overlay of structure of ADC(T57V)-PanZ complex (green and cyan) and ADC(WT)-PanZ complex (yellow and white).



Figure S2 a *Fo-Fc* difference electron density (green mesh) contoured at 3 rmsd and 2*Fo-Fc* electron density (grey mesh) contoured at 1 rmsd showing the presence of additional density in the region of the pyruvoyl group (green mesh). **b** final electron density, contoured as in (a) with a ketone hydrate modeled.



Figure S3 Size exclusion chromatography analysis of complex formation by PanD and PanZ. a&b SEC analysis of PanD (a black), PanD(K119A) (a red), PanZ (b black) and PanZ(R73A) (b red). All proteins elute as single species; analysis of peak fractions by SDSpage reveals that PanD electrophoreses as a tetramer if samples are not preboiled. c SEC analysis of WT PanD-PanZ complex. The complex elutes as a single species, Western blotting analysis confirms the presence of PanZ in the complex, trace activated PanD is visible in the boiled fractions. d SEC analysis of PanD(K119A) interaction with PanZ. PanZ chiefly elutes as separate species but a small proportion elutes in a complex with PanD(K119A). e SEC analysis of PanZ(R73A) interaction with PanD. The proteins elute individually.



22.5

Elution volume /mL

Figure S4 Relationship of Arg73 to AcCoA binding site in PanZ. Binding site for AcCoA in the PanD(WT)-PanZ.AcCoA crystal structure. Residue Arg73 forms a salt-bridge with residue Glu103 adjacent to the pantothenate moiety of AcCoA, potentially forming both van der Waals interactions and stabilizing the helix which forms the adenine binding pocket. 2*Fo-Fc* electron density contoured at 1 rmsd for AcCoA, Arg73 and Glu103.

Figure S5 Global fitting of EtdtCoA binding to PanZ by isothermal titration calorimetry. The sample of EtdtCoA contained trace impurities leading to a significant sloping heat of dilution (see red lines S5a). Four independent titrations were globally fitted in SEDPHAT to a single set of thermodynamic parameters but with independent baseline height and slope correction. Substoichiometric binding is due to copurification of the AcCoA with PanZ. **a** 85 μ M EtdtCoA titrated into 10 μ M PanZ, **b** & **c** 85 μ M EtdtCoA titrated into 18 μ M PanZ, **d** 85 μ M EtdtCoA titrated into 20 μ M PanZ

Figure S6 Estimation of minimum inhibitory concentration for growth of *E. coli* MG1655 and strains in which the *panD* locus has been mutated determined by growth in M9 media for 20 h at 37 °C. Pentyl pantothenamide inhibits growth of wild-type *E. coli* at 4 mg/mL (Black squares). Mutation of the *panD* locus to *panD*(K119A) which reduces the PanD-PanZ interaction affinity is insufficient to generate resistance (red circles) whereas incorporation of the *Bacillus subtilis* gene at the *panD* locus (SN218) is sufficient to generate resistance (blue triangles). Data are fitted to a Logistic model for growth inhibition with shared upper and lower limits.

Figure S7 Analysis of growth of *E. coli* MG1655 inhibited by pentyl pantothenamide. a β -Alanine supplementation inhibits growth of E. coli Growth of MG1655 in the presence of increasing concentrations of pentyl pantothenamide and 0.5 mM β -alanine indicates that cells grow to a lower final density in the presence of β -alanine, suggesting that overproduction of pantothenate under these conditions is detrimental to optimal growth. **b Pentyl pantothenamide does not effect growth rate**. Growth of MG1655 in increasing concentrations of pentyl pantothenamide (data also shown in figure 3b). The exponential growth rate is broadly unaffected by addition of pentyl pantothenamide, only the plateau position is affected (inset). c Final plateau growth density is a function of seeding density. Growth of *E. coli* MG1655 in the presence of 10 µg mL⁻¹ pentyl pantothenamide at varied seeding densities indicates a linear relationship between seeding density and the final growth plateau.

Additional experimental methods

Table A: Primers used	d for construction of <i>panD</i> mutants.
panDmutU	aaagtcgcgagccgtctccgcATGCATtaa (NsiI: ATGCAT)
panDmutL	atatCTTAAGaacggattcgctggagacga (AflII: CTTAAG)
panD(K14A)U	CGCGTGgccGTGACTCATGCGGACCTGCAC
panD(K14A)L	AGTCACggcCACGCGGTGGAGTTTGCCCTG
panD(K53A)U	AACGGCgccCGTTTCTCCACTTATGCCATC
panD(K53A)L	GAAACGggcGCCGTTGGTGACATTCCAGAT
panD(K115A)U	GAAATGgccCGTACCGCGAAAGCGATTCCG
panD(K115A)L	GGTACGggcCATTTCATTGTCGCCTTCAAA
panD(K119A)U	ACCGCGgccGCGATTCCGGTACAGGTTGCT
panD(K119A)L	AATCGCggcCGCGGTACGTTTCATTTCATT
Construction of pBA	AD24panZ(R73A)
Table B: Primers used	for construction of mutant PanZ expressing plasmids.
panZBADU40 (EcoRI: GAATTC)	acacGAATTCcccATGAAGCTGACCATCATTCGATTAGAA
panZL3	atatGCATGCcggcctacaagatccaaaga (SphI: GCATGC)

panZ(R43A)U	GCCGCGgcTTTTAACGAGCGCCTGCTCGCT
panZ(R43A)L	GTTAAAAgcCGCGGCGTAGATACGGTGGTT
panZ(N45A)U	CGTTTTgcCGAGCGCCTGCTCGCTGCCGTG
panZ(N45A)L	GCGCTCGgcAAAACGCGCGGCGTAGATACG
panZ(T72A)U	GAAGTCgCCCGCCGTCGCGGTGTGGGGGCAA
panZ(T72A)L	ACGGCGGGcGACTTCCCGCACGCGCAGGGA
panZ(R73A)U	GTCACCgcCCGTCGCGGTGTGGGGGCAATAT
panZ(R73A)L	GCGACGGgcGGTGACTTCCCGCACGCGCAG

Size-exclusion chromatography analysis

Size-exclusion chromatography analysis was carried out as described previously. Following purification, proteins were analysed using an Akta Prime Plus liquid chromatography system at a flow rate of 0.2 mL/min of 50 mM Hepes/KOH, 150 mM KCl, pH 7.6. For protein-interaction analysis 60 μ M PanD and 15 μ M PanZ were mixed and incubated at 4 °C for 60 min prior to analysis. Western blotting against PanZ was carried out using a rabbit polyclonal antibody to PanZ produced under contract by Biogate Co., Japan.

Synthesis of small molecules

N-pentyl pantothenamide

Calcium pantothenate (2.0 g, 8.3 mmol) was dissolved in H₂O (~20 mL) and passed through an Amberlite IR-120 (H⁺) column. This was washed with 2×20 mL H₂O and eluants were combined and lyophilised overnight to leave pantothenic acid as a colourless oil. The oil was dissolved in DMF (10 mL) and amylamine (1.16 mL, 10 mmol) and diphenylphosphine azide (2.24 mL, 10 mmol) were added. The mixture was cooled to 0 °C and triethylamine (1.39 mL, 1.2 mmol) was added followed by stirring for 5 hours. The DMF was removed under reduced pressure to leave a white oil which was purified by flash chromatography three times (silica; 5% v/v methanol-CH₂Cl₂ and gradient elution 1-10% v/v methanol-CH₂Cl₂) due to co-elution in the presence of traces of DMF. Fractions were combined and evaporated under reduced pressure to yield a colourless oil which was lyophilised overnight to leave a colourless solid on standing (0.84 g, 35%). TLC (CH₂Cl₂/MeOH/AcOH 94:5:1 (v/v)): R_f: 0.19; ¹H NMR (500 MHz, CDCl₃): δ 7.45 (1H, t (br), J= 6.3 Hz, COHCONH), 6.09 (1H, t (br), J= 5.4 Hz, NH), 4.26 (1H, d, J= 5.5 Hz, HC-OH), 3.99 (1H, d, J= 5.3 Hz, CH₂OH), 3.73 (1H, t, J= 5.6 Hz, *H*C-OH), 3.56 (2H, m, C*H*₂OH), 3.49 (2H, d, *J*= 5.5 Hz, C*H*₂CH₂CO), 3.21 (2H, q, *J*= 7.2, CH₂CH₂CO), 2.43 (2H, t, J= 6.0 Hz, NHCH₂-C₄H₉), 1.49 (2H, m, CH₂-C₃H₇), 1.30 (4H, m, C₂*H*₄-CH₃), 1.00 (3H, s, CH₂CH₃CH₃), 0.93 (3H, s, CH₂CH₃CH₃), 0.90 (3H, t, *J*=6.7, CH₂CH₃); ¹³C NMR (125 MHz, CDCl₃): δ 197.8, 173.4, 171.2, 77.7, 70.9, 39.7, 35.8, 35.4, 29.1, 29.0, 22.2, 21.4, 20.4, 13.8; IR v_{max}/cm⁻¹: 3280 (N-H), 3000-2800 (OH, broad), 1642 (C=O); HRMS (*m/z*): [M+Na]⁺ calcd for C₂₅H₃₀NO₇Na, 311.1941; found, 311.1945.

N-pentylpantothenamide-4'-O-dibenzylphosphate

N-pentylpantothenamide (300 mg, 1.04 mmol) was dissolved in dry acetonitrile (12 mL) under N_2 . A tetrazole solution in acetonitrile (0.45 M, 2.31 mL, 1.04 mmol) and dibenzyl-N,N-diisopropyl-phosphoramidite (0.35 mL, 1.04 mmol) were added and the reaction mixture stirred for 5 min at room temperature. mCPBA (269.2 mg, 1.56 mmol) was added and the

solution stirred for 2 h at room temperature. The product was concentrated *in vacuo*, extracted with ethyl acetate (3 × 20 mL), and the combined organic extracts washed with 1M H₂SO₄ (2 × 5 mL) and 1M NaHCO₃ (2 × 5 mL) before drying (MgSO₄) and concentration *in vacuo*. The product was purified by flash column chromatography (MeOH/CH₂Cl₂ 7:93) to yield N-pentylpantothenamide-4'-O-dibenzylphosphate as a colourless oil (415.3 mg, 72.7%) ¹H NMR (500 MHz, CDCl₃): δ 7.57 (1H, t(br), J = 6.2 Hz, NH), 7.51 (1H, s(br), OH), 7.49 (1H, s(br), OH), 7.42-7.24 (10H, m, H₁₅, H₁₆, H₁₇), 6.87 (1H, t(br), J = 5.7 Hz, NH), 5.16-4.98 (4H, m, H₁₄), 4.04 (1H, dd, J = 9.9, 6.1 Hz, H₁), 3.97 (1H, s, H₄), 3.72 (1H, dd, J = 9.9, 6.1 Hz, H₁) 3.57 (2H, q, J = 6.2 Hz, H₆), 3.2 (2H, q, J = 6.5 Hz, H₇), 2.56-2.53 (2H, m, H₉), 1.48 (2H, p, J = 7.3 Hz, H₁₀), 1.33-1.22 (4H, m, H₁₁, H₁₂), 1.05 (3H, s, H₃), 0.91-0.83 (6H, m, H₃, H₁₃); IR (V_{max}/cm⁻¹): 3300 (N-H), 3095-2873 (OH, broad), 1638 (C=O);

N-pentylpantothenamide-4'-O-phosphate

N-pentylpantothenamide-4'-O-dibenzylphosphate (415.3 mg, 0.75 mmol) was dissolved in 9:1 CH₃OH/H₂O (20 mL) and stirred under N₂. Pd/C (10% (*wt/wt*), 41.5 mg) was added and the suspension was maintained under a hydrogen atmosphere (1 atm, balloon) at room temperature with stirring for 6 h. A second portion of Pd/C (10% (*wt/wt*), 41.5 mg) was added and the before stirring under H₂ for a further 2h. The solution was filtered through celite and concentrated *in vacuo*. The product was extracted with water (3 × 20 mL) and lyophilised to yield the title compound as an orange powder (47.69 mg, 17.1 %) ¹H NMR (500 MHz, D₂O): δ 3.95 (1H, s, H₄), 3.78 (1H, dd, J = 9.7, 4.8 Hz, H₁), 3.59 (1H, dd, J = 9.7, 4.8 Hz, H₁) 3.43 (2H, m, H₆), 3.07 (2H, m, H₇), 2.4 (2H, t, J = 6.4 Hz, H₉), 1.41 (2H, p, J = 7.0 Hz, H₁₀), 1.21 (4H, m, H₁₁, H₁₂), 0.9 (3H, s, H₃), 0.83 (3H, s, H₃), 0.79 (3H, t, J = 6.8 Hz, H₁₃); ¹³C NMR (100 MHz, D₂O): δ 174.79, 173.60, 133.80, 129.61, 128.70, 74.40, 71.59, 39.51, 38.33, 28.33, 27.90, 21.68, 20.58, 18.60, 13.24; ³¹P NMR (400 MHz, D₂O): δ 0.12; IR (V_{max}/cm⁻¹): 3310 (N-H), 3097-2871 (OH, broad), 1637 (C=O);

Ethyldethiacoenzyme A

N-pentyl 4-dibenzylphosphopantothenamide (10.5 mM) was added to a mixture of both CoaD (9 µM) and CoaE (11 µM) in 50 mM Tris-HCl buffer (pH 7.6) in the presence of MgCl₂ (5 mM) and ATP (50 mM) (Final volume 900 µL) before incubation at 37 °C for 2-4 hours Production of EtdtCoA was analysed by LCMS. CoaD and CoaE were precipitated by heating at 95 °C for 15 min and removed by centrifugation. The supernatant was purified by reverse phase HPLC (C₁₈-silica) using a 5-95% 50 mM KH₂PO₄ (pH 5.3)/MeOH gradient to remove separation of the ATP/AMP from the EtdtCoA. The MeOH was removed in vacuo and the samples adjusted to pH 7.6 using 5 M NaOH before being lyophilized. The product was resuspended in a minimum volume of H₂O and desalted using a Sephadex G-10 column to yield the title compound (1.54 mg, 21%). EtdtCoA was quantified by UV absorption at 257 nm. (ε₂₅₇ = 16840 M⁻¹ cm⁻¹). ¹H NMR (750 MHz, D₂O) 8.45 (1H, s, purine-2H), 8.17 (1H, s, purine-8H), 6.07 (1H,d 6.9, ribose-1'H), 4.72 (1H, br s, ribose-4'H), 4.47 (1H br s, ribose-2'H), 4.13 (2H, br s, ribose-5'H), 3.90 (1H, s, ribose-4'H), 3.71 (1H, dd, J = 9.5,4.9 Hz, C(CH₃)₂.CH₂OP), 3.68 (0.6H, ddd, glycerol), 3.63 (1H, s, C(CH₃)₂CH(OH)CO), 3.55 (1H, dd, glycerol), 3.46 (1H, dd, glycerol), 3.43 (1H, dd 9.5, 4.9, -C(CH₃)₂.CH₂OP), 3.37 (1H, dt, J= 14, 6.7 Hz, NHCH₂CH₂CO), 3.33 (1H, dt, J= 14, 6.7 Hz, NHCH₂CH₂CO), 2.98 (2H, dt J= 6.9, 3.0 Hz, NHCH₂CH₂CH₂), 2.33 (2H, t, J= 6.6 Hz, NHCH₂CH₂CO), 1.31 (2H, p, J = 7.0 Hz, NHCH₂CH₂CH₂) 1.08 (4H, m, CH₂CH₂CH₃), 0.76 (3H, s, C(CH₃)₂), 0.72 (3H, t, J = 6.9 Hz, CH₂CH₂CH₃), 0.62 (3H, s, C(CH₃)₂); HRMS (*m*/*z*): [MH]⁺ 778.1961 (C₂₄H₄₃N₇O₁₆P₃ requires 778.1979), [MNa]⁺ 800.1782 (C₂₄H₄₂NaN₇O₁₆P₃ requires 800.1799), [M-H+2Na]⁺ 822.1601 (C₂₄H₄₁Na₂N₇O₁₆P₃ requires 822.1618), [M-2H+3Na]⁺ 844.1425 (C₂₄H₄₀Na₃N₇O₁₆P₃ requires 844.1437).

ZA1-031 Name Zoe Arnott Room No 1.49 Sample ZA1-031z

-18000

Confirm/Find Formula Results

The section below shows the results of formula calculation. If an expected formula was provided and found these are the results that are listed. If no formula was provided or no matches were found the system has attempted to determine the formula constrained by the parameters listed to the left

Meas.m/z	Ion Formula	Z	m/z	err [mDa]	err [ppm]	mSigma	Score	Sum Formula	Adduct
289.212235	C14H29N2O4	1+	289.212184	0.1	0.2	12.9	100.00	C14 H28 N2 O4	M+H
311.194541	C14H28N2NaO4	1+	311.194128	0.4	1.3	11.9	100.00		M+Na
327.167961	C14H28KN2O4	1+	327.168065	0.1	0.3	5.9	100.00		M+K
599.400086	C28H56N4NaO8	1+	599.399035	-1.1	-1.8	21.2	100.00		2M+Na

Bruker Compass DataAnalysis 4.1

Analysis Name

8.5

-25000

